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Urotensin II and the Circulatory System
Kwok-Leung Ong, Bernard M.Y. Cheung, Karen Siu-Ling Lam
Urotensin II (UII), first isolated from the spinal cord of teleost fish, is the most potent vasoconstrictor known.
It is more potent than endothelin-1 and acts through UT-II, a seven-transmembrane-domain, G-protein-coupled
receptor. Human UII is an 11-amino-acid cyclic peptide that is expressed in various tissues, including the
central nervous system, heart, kidney, and blood vessels. It circulates in human plasma, and its plasma level is
elevated in renal failure, congestive heart failure, diabetes, and portal hypertension. In the kidney, UII has
vasodilatory and natriuretic effects, mediated through nitric oxide. The development of UII-receptor antagonists
may provide a useful research tool, and a novel treatment for cardiorenal diseases. [Hong Kong J Nephrol
2005;7(1):9–13]
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INTRODUCTION
Urotensin II (UII) was first isolated from the spinal cord
of teleost fish and has been recognized as a hormone in
the neurosecretory system of such fish for over 30 years
[1,2]. It is the most potent vasoconstrictor known, being
more potent than endothelin-1 (ET-1) [2]. This brief
review summarizes what is known about UII and its
receptor (UT-II), their function and relation to cardio-
vascular and renal diseases.
UII AND ITS RECEPTOR UT-II
UII is a cyclic peptide with an amino acid sequence
similar to that of somatostatin (Figure 1). UII isoforms
from human, monkey, pig, rat, mouse and goby contain
a conserved C-terminal cyclic-hexapeptide sequence
(Cys-Phe-Trp-Lys-Tyr-Cys) that confers most of the
biologic activity, and an N-terminal that differs in length
and sequence depending on the animal species [3].
Human UII is an 11-amino-acid cyclic peptide
derived from a large precursor molecule (prepro-UII).
The gene encoding the peptide, UTS2, is located at
1p36–p32 and contains five exons. Prepro-UII mRNA
has been found in heart, aorta, vascular endothelial and
smooth muscle cells, brain, spinal cord, kidney, lung,
liver, skeletal muscle, adrenal gland, pituitary, spleen,
the small intestines and colon [3]. UII-like immuno-
activity is present abundantly in the epithelial cells
of the distal convoluted and collecting tubules, and
in the endothelial cells of the renal capillaries [4]. Thus,
the kidney is an important site of UII synthesis.
In man, the UII receptor, UT-II, is a 389-amino-
acid, G-protein-coupled receptor with seven trans-
membrane domains (Figure 2). The gene coding for
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human UT-II does not have an intron and is located at
17q25.3 in the long arm of chromosome 17 [5]. UT-II
is found in human brain, spinal cord, ventricular myo-
cardium, vascular endothelial and smooth muscle
tissues, kidney cortex, and thyroid, with the highest
density in skeletal muscle and the cerebral cortex [6].
The distribution of UII and UT-II suggests that UII
may act as a local or circulating vasoactive hormone
in cardiovascular regulation. Interestingly, UT-II has
not been found in veins, and UII does not constrict iso-
lated preparations of veins, except the saphenous
and umbilical veins [6].
UT-II is coupled to the Gq/11 signal-transduction
pathway, the activation of which leads to increased
levels of inositol phosphate and mobilization of intra-
cellular calcium ions [2,7]. Human UII induces arterial
smooth muscle contraction, actin stress fiber formation
and proliferation through activation of the small RhoA
guanosine triphosphatase and its downstream effector,
Rho-kinase [8]. UII also induces vascular smooth
muscle proliferation via activation of integrin-mediated
signaling pathways and phosphorylation of extracellular
signal-regulated kinase (ERK) [9].
PHYSIOLOGIC ROLES OF UII
The vascular actions of UII vary with species and site.
UII also influences sodium transport, and lipid and
glucose metabolism, at least in fish [1]. The con-
centration of UII in the urine is more than three orders
of magnitude greater than that in the plasma, sug-
gesting that urinary UII is produced within the kid-
ney [10]. Infusion of synthetic UII into the renal artery
of anesthetized rats increases renal blood flow and
glomerular filtration rate (GFR) in a dose-dependent
manner; these effects can be completely abolished by
adding a nitric oxide synthase inhibitor [11]. UII may
play a role in regulating GFR via tubuloglomerular
feedback and the reflex control of GFR [4]. UII also
increases urinary water and sodium excretion by
stimulating nitric oxide production, which, in turn,
inhibits tubular ion transport activity [11]. Hence, in
the kidney, UII exerts vasodilatory and natriuretic
effects.
In the rat, UII produces both endothelium-
independent vasoconstriction and endothelium-
dependent vasodilatation [2,11,12]. In human arteries,
UII is about 50 times more potent than ET-1, but the
maximum response is significantly lower than that
achieved by ET-1, and 30% of vessels do not respond
to UII [6]. Conversely, UII relaxes the vasoconstriction
induced by ET-1 in small pulmonary arteries and
systemic resistance arteries [13]; this might be due to
the release of nitric oxide and endothelium-derived
hyperpolarizing factor from an intact endothelium.
In the rat renal artery, UII induces nitric oxide syn-
thesis in the endothelium and subsequent vasodilata-
tion [11].
Intravenous administration of low-dose UII in
monkeys increases cardiac output and reduces pe-
ripheral vascular resistance [2]. Higher doses cause
cardiovascular collapse that may be lethal. Recently,
the cat was found to be a useful model to study, since
isolated feline arteries are highly responsive to UII [14].
Infusion of UII in the cat doubled systemic vascular
resistance and blood pressure without markedly altering
heart rate or cardiac output [14]. While Bohm and Pernow
showed that UII caused potent vasoconstriction in man,
with a dose-dependent decrease in forearm blood flow
[15], Wilkinson et al found no increase in blood pressure
or peripheral vascular resistance after infusion of UII
in healthy men [16]. Moreover, intravenous infusion
of UII did not affect systemic hemodynamics or arterial
Figure 1. Structure of human urotensin II. Figure 2. Simplified, diagrammatic representation of the urotensin
II receptor.
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stiffness, even with a 100-fold increase in plasma UII
levels [17]. The absence of systemic vasoconstric-
tion after UII infusion may be due to the modulating
effect of other vasoactive substances such as nitric
oxide. Further studies with a UT-II antagonist would
clarify the physiologic role of UII in regulating vessel
tone.
UII also possesses cardiostimulant effects in the
human heart in vitro [18]. Human UII causes a
concentration-dependent increase in contractile force
with no change in duration of contraction in right atrial
trabeculae from non-failing hearts, and a small increase
in contractile force in right ventricular trabeculae from
explanted hearts [18].
POTENTIAL ROLES OF UII IN HUMAN DISEASE
UII circulates in human plasma, and plasma levels of
UII are elevated in renal failure [19,20], congestive heart
failure [21,22], diabetes mellitus [23], and portal
hypertension caused by liver cirrhosis [24]. Plasma
levels of UII in patients with renal dysfunction who
are not on hemodialysis, or who are on hemodialysis,
are respectively 2-fold or 3-fold greater than in healthy
individuals; this may be due to increased production or
decreased excretion of UII [20]. Although there is no
correlation between blood pressure and urinary UII
level, an increased urinary UII level is observed in pa-
tients with essential hypertension, patients with both
glomerular disease and hypertension, and patients with
renal tubular disorders, but not in normotensive patients
with glomerular disease [10]. UII may also have a
mitogenic role in the human renal system; this is
suggested by the abundant expression of UII in renal
clear-cell carcinoma [4].
Plasma levels of UII are elevated in patients with
diabetes, independent of blood glucose levels. UII
inhibits insulin secretion in the rat pancreas in response
to both glucose and arginine [25]. Interestingly, a single
nucleotide polymorphism in the UTS2 gene, T21M, is
correlated with genetic susceptibility to type 2 diabetes
in Han people, while the S89N polymorphism in UTS2
has been associated with type 2 diabetes in Japanese
individuals [26,27].
As UII is a vasoconstrictor, its role in hypertension
is worthy of investigation. Normotensive and hyperten-
sive patients have similar cerebrospinal fluid (CSF)
levels of UII, but in hypertensive patients, CSF levels
of UII correlate with mean arterial blood pressure [28].
However, a recent study of the role of UII in hyper-
tension showed that it may have a causative role in
hypertension and its complications since plasma levels
of UII were raised in hypertensive patients relative to
normotensive controls and were directly related to
systolic blood pressure [29].
UII and UT-II are found in the heart and blood
vessels, including atherosclerotic plaques, thus sug-
gesting a role in cardiovascular diseases [19]. UII
acts synergistically with mildly oxidized low-density
lipoprotein to induce vascular smooth muscle cell
proliferation [30]. In addition, serotonin (5-hydroxy-
tryptamine) contained in platelets interacts synergis-
tically with UII to induce such cellular prolifera-
tion, which may contribute to the rapid development
of atherosclerosis in hypertensive vascular disease
[31]. Moreover, atherosclerosis is associated with the
diminished production of endothelial nitric oxide.
When endothelial dysfunction exists, the vasocon-
stricting effect of UII is unopposed and unmasked.
Zuo et al demonstrated that hypertrophy of neona-
tal rat cardiomyocytes cultured in vitro can be induced
by UII [32]. The hypertrophy of cardiac myocytes was
mediated by the mitogen-activated protein kinases
ERK1/2 and p38 [33].
Expression of UII and UT-II is upregulated in
patients with end-stage heart failure [34]. UII is one
of several neurohormonal systems activated in con-
gestive heart failure [21,35,36]. An inverse correla-
tion exists between UII expression or plasma UII
concentration and ejection fraction [34,36]. UII may
increase cardiac contractility [18] and peripheral vas-
cular tone [37]. Although increased contractility may
be beneficial in the short term, prolonged activation
might lead to myocardial remodelling. Indeed, UII
induces cardiac fibroblast proliferation and collagen
type I mRNA expression [38]. Interestingly, UII causes
vasodilatation in the skin vessels of healthy individuals,
but causes vasoconstriction in patients with heart failure
[37].
UII may play a role in myocardial ischemia and
acute myocardial infarction. In the myocardium of rats
with chronic hypoxia, UT-II expression is increased
[39], and around infarct zones and in inflammatory
cells, there is increased expression of UII and UT-II
[40].
CONCLUSION
UII is the most potent vasoconstrictor known, and it
also stimulates nitric oxide production. Thus, it may
play an important role in regulating vascular tone and
blood flow. There is increasing evidence that UII is
associated with atherosclerosis, congestive heart failure,
diabetes, hypertension, and renal dysfunction. More
research is needed to elucidate the pathophysiology of
UII and its receptor, UT-II, as well as the urotensin-
converting enzyme(s) that produces UII from prepro-
UII. The development of UT-II antagonists may provide
both a useful research tool and a novel treatment for
cardiorenal diseases.
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